Lilly to present new data on Foundayo, Mounjaro, and retatrutide at the American Diabetes Association’s 86th Scientific Sessions

Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapy. New analyses from the ATTAIN programme highlight Foundayo’s profile across patient populations central to the future of cardiometabolic care, including women at every stage of menopause. Pivotal Phase 3 results also showed that retatrutide, a first in class triple receptor agonist, produced powerful results in obesity, type 2 diabetes, and other complications.

Eli Lilly and Company, the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron), and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association’s 86th Scientific Sessions, taking place 5 to 8 June in New Orleans. Taken together, the findings position Lilly to lead the next era of cardiometabolic care with a differentiated suite of approved and investigational medicines designed to expand choice for the millions of people living with obesity, diabetes, and related conditions.

“No two patients with obesity or diabetes are alike, and their needs evolve over time. That’s exactly why choice matters,” said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. “The data we’re presenting at ADA, including pivotal Phase 3 results for retatrutide and Foundayo, the only oral GLP-1 taken without food or water restrictions, demonstrate our ability to meet patients wherever they are and wherever they’re headed.”

Selected Lilly presentations at ADA 2026

The retatrutide symposium will be held on Saturday, 6 June 2026, from 1:30 to 3:00 p.m. CDT. This ADA sponsored symposium will share Phase 3 findings for retatrutide, an investigational once weekly GIP, GLP-1, and glucagon triple receptor agonist, across two studies. In TRIUMPH-1, retatrutide produced powerful weight loss of up to an average of 70.3 lbs (28.3%) at 80 weeks in adults with obesity. In TRANSCEND-T2D-1, retatrutide reduced A1C by up to an average of 2.0% and weight by up to an average of 36.6 lbs (16.8%) at 40 weeks in adults with type 2 diabetes.

The Foundayo (orforglipron) symposium will take place on Monday, 8 June 2026, from 1:30 to 3:00 p.m. CDT. This ADA sponsored symposium will share Phase 3 results for Foundayo, the only oral GLP-1 that can be taken without food or water restrictions, across three studies in the ACHIEVE type 2 diabetes programme. In ACHIEVE-2, Foundayo reduced A1C by up to 1.7%, compared with 0.8% on dapagliflozin, at 40 weeks. In ACHIEVE-3, Foundayo was superior to oral semaglutide in type 2 diabetes, delivering greater A1C reduction and 73.6% greater relative weight loss at 52 weeks. In ACHIEVE-5, Foundayo reduced A1C by up to 2.1%, compared with 0.8% on placebo, when used alongside insulin glargine at 40 weeks.

Foundayo (orforglipron) posters include an ATTAIN-1 and ATTAIN-2 subgroup analysis, which found that Foundayo was associated with significant weight loss across all stages of menopause, including more than 14% weight reduction in women in peri menopause or post menopause within ATTAIN-1. An ATTAIN-1 post hoc analysis also found that Foundayo was linked to meaningful improvements in markers of insulin sensitivity and beta cell function in adults with obesity, regardless of pre diabetes status.

Mounjaro (tirzepatide) posters include findings from SURPASS-CVOT, in which Mounjaro and dulaglutide produced improvements in quality of life and daily functioning over multiple years of treatment, and from SURPASS-EARLY, which showed that Mounjaro improved physical, psychosocial, and quality of life outcomes in adults with early type 2 diabetes.

---

---

Related Topics and Keywords

elli lilly, Foundayo, mounjaro, mounjro, retatrutide